临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
GDC-1971
CAS号:2377352-49-1
分子式: C25H26N8O 分子量: 454.54
产品形式: Free base
研发状态: Recruiting
研发用途: Colorectal Cancer; Non-Small Cell Lung Cancer
研究机构: Genentech Inc.
研发日期: January 8 2024
研发阶段: Phase 1
GDC-1971 (compound 199) is a SHP2 inhibitor.
Zn-C3
CAS号:2376146-48-2
分子式: C29H34N8O2 分子量: 526.63
产品形式: Free base
研发状态: Recruiting
研发用途: Metastatic Colorectal Cancer
研究机构: K-Group Beta Inc. a wholly owned subsidiary of Zentalis Pharmaceuticals Inc; Pfizer
研发日期: February 27 2023
研发阶段: Phase 1 : Phase 2
ZN-c3 is an oral active, highly effective and selective Wee1 inhibitor with IC50 of 3.9 nM, which can be used in cancer research.
LY-3475070
CAS号:2375815-63-5
分子式: C15H18N4O2 分子量: 286.33
产品形式: Free base
研发状态: Completed
研发用途: Advanced Cancer
研究机构: Eli Lilly and Company; Merck Sharp & Dohme LLC
研发日期: January 16 2020
研发阶段: Phase 1
LY-3475070 is a potent, selective and orally bioavailable inhibitor of the ectoenzyme CD73 (cluster of differentiation 73, 5'-ecto-nucleotidase, 5'-NT, ecto-5'-nucleotidase).
Alsterpaullone
中文名称:阿特波龙
CAS号:237430-03-4
分子式: C16H11N3O3 分子量: 293.28
产品形式: Free Base
研发状态: Not yet recruiting
研发用途: Kidney Failure Chronic
研究机构: Resverlogix Corp
研发日期: November 22 2024
研发阶段: Phase 1 : Phase 2
Alsterpaullone (Alp, 9-Nitropaullone, NSC 705701) is a potent inhibitor of CDK with IC50 of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively. Alsterpaullone also acts as a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 of both 4 nM for GSK-3α and GSK-3β. Alsterpaullone induces apoptosis by activation of caspase-9. Alsterpaullone has antitumor activity and possesses potential for the treatment of neurodegenerative and proliferative disorders.
Sunvozertinib
CAS号:2370013-49-1
分子式: C29H35ClFN7O3 分子量: 584.08
产品形式: Free Base
研发状态: Recruiting
研发用途: Non-small Cell Lung Cancer
研究机构: Dizal Pharmaceuticals
研发日期: February 15 2023
研发阶段: Phase 2
DZD9008 (Sunvozertinib) is an oral, potent, irreversible, wild type-selective EGFR inhibitor against EGFR or HER2 Exon20ins and other mutations with IC50 ranging from 0.4 nM to 2.1 nM for mutant EGFR.
Difluprednate
中文名称:二氟孕甾丁酯
CAS号:23674-86-4
分子式: C27H34F2O7 分子量: 508.55
产品形式: free base
研发状态: Completed
研发用途: Inflammation
研究机构: Sirion Therapeutics Inc.
研发日期: Jan-08
研发阶段: Phase 3
Difluprednate (difluoroprednisolone butyrate acetate, DFBA, CM 9155) is a synthetic difluorinated prednisolone derivative, it is originally developed for dermatologic applications.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
